BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BioXcel Therapeutics, Inc. (BTAI)
Today's Latest Price: $47.72 USD
Updated Jun 5 4:00pm
Add BTAI to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BTAI Stock Price Chart More Charts
BTAI Price/Volume Stats
| Current price | $47.72 | 52-week high | $53.10 |
| Prev. close | $49.11 | 52-week low | $3.76 |
| Day low | $47.31 | Volume | 257,159 |
| Day high | $51.30 | Avg. volume | 576,635 |
| 50-day MA | $35.20 | Dividend yield | N/A |
| 200-day MA | $18.65 | Market Cap | 964.47M |
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Loading social stream, please wait...